Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

This is Phase IV, randomized, multi arm, multicenter, low interventional clinical trial, aiming to evaluate if treatment of primary tumor in mRCC patients with initial benefit to anti-PD1- based therapy (SOC) can improve the overall survival. All patients eligible according to inclusion and exclusion criteria will be enrolled and randomized to different treatment options based on tumor extension of the primary kidney cancer. Those with primary kidney cancer ≤ 4 cm will be randomized 1:1:1 to receive: * Cytoreductive Nephrectomy + standard of care (SOC) or * RT on primary tumor + SOC or SOC

Trial Details

NCT ID

NCT06903312

Phase

PHASE4

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Deferred Cytoreductive Nephrectomy + medical treatment
Radiotherapy + medical treatment
Medical therapy

Locations (sample)

Roma, Italy|44.99364,11.10642

Key Eligibility Criteria

Informed consent obtained before any study-specific procedures. Patients must be able to understand and be willing to sign a written informed consent.
Male or female patient ≥18 years of age.
Histological or cytological documentation of renal cell carcinoma with predominantly clear cell histology.
Evidence of primary renal cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →